Fulvestrant: one option of several
64 studies: a test or a strategy chooses among drugs. Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBCNot yet recruitingNCT07935226Phase 2Report a problem
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingNCT07802626Phase 3Report a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingNCT07729046Phase 2Report a problem
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2Report a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3Report a problem
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2Report a problem
- T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationNCT06481956Phase 2Report a problem
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2Report a problem
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3Report a problem
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingNCT06339281Phase 2Report a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2Report a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingNCT06044623Phase 3Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2Report a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2Report a problem
- Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2Report a problem
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingNCT04923542Phase 1/2Report a problem
- Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast CancerRecruitingNCT03750396Phase 2Report a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingNCT02476786Phase 2Report a problem
- Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerCompletedNCT05101564Phase 2Results postedReport a problem
- Biology Guided Therapy for Breast Cancer for ER PositiveTerminatedNCT04965688Phase 2Results postedReport a problem
- A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results postedReport a problem
- Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based CohortsTerminatedNCT04657679Phase 4Results postedReport a problem
- Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerCompletedNCT03633331Phase 2Results postedReport a problem
- Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03007979Phase 2Results postedReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedReport a problem
- Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingNCT02778685Phase 2Results postedReport a problem
- Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerCompletedNCT02692755Phase 2/3Results postedReport a problem
- Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCompletedNCT02630693Phase 2Results postedReport a problem
- A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast CancerCompletedNCT02384239Phase 2Results postedReport a problem
- Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerCompletedNCT02366130Phase 2Results postedReport a problem
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results postedReport a problem
- Phase II Study of Everolimus Beyond ProgressionTerminatedNCT02269670Phase 2Results postedReport a problem
- Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal WomenCompletedNCT00545077Phase 3Results postedReport a problem
- Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedNCT00405938Phase 2Results postedReport a problem
- Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyActive, not recruitingNCT06957379Phase 2Report a problem
- First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2Report a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2Report a problem
- Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer PatientsStatus unknownNCT05670054Phase 3Report a problem
- Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast CancerStatus unknownNCT05295043Not applicableReport a problem
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1Report a problem
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2Report a problem
- Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeTerminatedNCT05207709Phase 3Report a problem
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4Report a problem
- Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2Report a problem
- ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLCompletedNCT04603183Phase 2Report a problem
- Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerTerminatedNCT04460430Phase 2Report a problem
- Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast CancerCompletedNCT04352777Phase 2Report a problem
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast CancerWithdrawnNCT04316169Phase 1Report a problem
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast CancerActive, not recruitingNCT04158362Phase 3Report a problem
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3Report a problem
- PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)CompletedNCT03809988Phase 2Report a problem
- Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2Report a problem
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedNCT03554044Phase 1Report a problem
- Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineCompletedNCT03462251Phase 3Report a problem
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingNCT03425838Phase 3Report a problem
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).CompletedNCT03355157Phase 4Report a problem
- CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDOCompletedNCT03227328Phase 2Report a problem
- Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerStatus unknownNCT03204734Phase 2Report a problem
- Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2Report a problem
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2Report a problem
- Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2Report a problem
- Detect V / CHEVENDO (Chemo vs. Endo)Active, not recruitingNCT02344472Phase 3Report a problem
- Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesStatus unknownNCT02238509Phase 2Report a problem
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast CancerCompletedNCT01989780Phase 2Report a problem